Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0HDRBW
ADC Name	Olaratumab-Compound (Ia)
Synonyms	Olaratumab Compound (Ia) Click to Show/Hide
Organization	Orum Therapeutics, Inc.
Drug Status	Investigative
Indication	In total 2 Indication(s) Chondrosarcoma [ICD11:2B50] Investigative Rhabdomyosarcoma [ICD11:2B55] Investigative
Drug-to-Antibody Ratio	8
Structure
	3D MOL	2D MOL
Antibody Name	Olaratumab		Antibody Info
Antigen Name	Platelet-derived growth factor receptor alpha (PDGFRA)		Antigen Info
Payload Name	NeoDegrader P1		Payload Info
Therapeutic Target	Protein cereblon (CRBN)		Target Info
Linker Name	Olaratumab-Compound (Ia) linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.37	nM	H-EMC-SS cells	Extraskeletal myxoid chondrosarcoma
Half Maximal Inhibitory Concentration (IC50)	2.36	nM	A-204 cells	Embryonal rhabdomyosarcoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.37 nM	Positive PDGFRA expression (PDGFRA+++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Extraskeletal myxoid chondrosarcoma	H-EMC-SS cells		CVCL_1238
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.36 nM	Positive PDGFRA expression (PDGFRA+++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Embryonal rhabdomyosarcoma	A-204 cells		CVCL_1058

References

Ref 1	Neodegrader conjugates; 2021-10-07.